The phase 1, open-label, PET trial designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.

Trial Identifier:	D7930C00003
Sponsor:	AstraZeneca
Collaborator:	Clinical Trial Consultants (CTC) Karolinska Institutet
Start Date:	May 2025
Primary Completion Date:	February 2026
Study Completion Date:	February 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
SE	Solna, SE, 171 64
SE	Stockholm, SE, 17176

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.